Eris Lifesciences Rating ‘Buy’; Growth prospects are ahead of the industry
Earnings CAGR of 17% is estimated over FY21-24e; coverage initiated with ‘Buy’ rating and TP of `870 We initiate coverage on Eris Lifesciences (ERIS) with a Buy rating and a target price of Rs 870. In just 14 years (founded in CY07), ERIS has built a pure-play Branded Formulation business, with a revenue of Rs …
Eris Lifesciences Rating ‘Buy’; Growth prospects are ahead of the industry Read More »